אלפא D 3 טיפות Israel - Ibrani - Ministry of Health

אלפא d 3 טיפות

teva pharmaceutical industries ltd, israel - alfacalcidol - טיפות - alfacalcidol 0.25 mcg - alfacalcidol - alfacalcidol - renal bone disease. hypoparathyroidism. rickets and osteomalacia. osteoporosis. primary and tertiary hyperparathyroidism. neonatal hypocalcemia.

אלפא די 3 0.5 מק"ג Israel - Ibrani - Ministry of Health

אלפא די 3 0.5 מק"ג

teva pharmaceutical indust.ltd - alfacalcidol 0.5 mcg - capsules - alfacalcidol - renal bone disease . hypoparathyroidisim. rickets and osteomalacia. osteoporosis. primary and tertiary hyperparathyroidism. neonatal hypocalcemia.

טבאלפא די 3  0.25 מקג Israel - Ibrani - Ministry of Health

טבאלפא די 3 0.25 מקג

teva pharmaceutical industries ltd, israel - alfacalcidol - קפסולות ג'לטין רכות - alfacalcidol 0.25 mcg - alfacalcidol - alfacalcidol - renal bone disease (renal osteodystrophy), hypoparathyroidism, hyperparathyroidism (with bone disease) - primary and tertiary. neonatal hypocalcemia, rickets and osteomalacia, osteoporosis.

טבאלפא 1.0 מקג Israel - Ibrani - Ministry of Health

טבאלפא 1.0 מקג

teva pharmaceutical industries ltd, israel - alfacalcidol - קפסולות ג'לטין רכות - alfacalcidol 1 mcg - alfacalcidol - alfacalcidol - renal bone disease (renal osteodystrophy), hypoparathyroidism, hyperparathyroidism (with bone disease) - primary and tertiary. neonatal hypocalcemia, rickets and osteomalacia, osteoporosis.

ווטריינט 200 מג Israel - Ibrani - Ministry of Health

ווטריינט 200 מג

novartis israel ltd - pazopanib as hydrochloride - טבליות מצופות פילם - pazopanib as hydrochloride 200 mg - pazopanib - pazopanib - renal cell carcinoma (rcc)votrient is indicated in adults for the first line treatment of advanced renal cell carcinoma (rcc) and for patients who have received prior cytokine therapy for advanced disease.soft tissue sarcoma (sts)votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (sts) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.